Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection

Frontiers in Oncology

Julia V. Pavlova¹  Andrey N. Shibaev¹  Konstantin S. Sorokin²  Marina Y. Zemskova²  Maria V. Marinets⁴  Andrey V. Sivkov⁴ 

[1] Department of Urology, M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russia;Department of the Research, Prostagnost LLC, Moscow, Russia;G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center, Pushchino Center for Biological Research of the Russian Academy of Sciences, Pushchino, Russia;N.A. Lopatkin Research Institute of Urology and Interventional Radiology, Branch of FSBI National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia;

关键词: prostate cancer;    urine;    biomarker;    integrin alpha V;    cancer diagnostic marker;    non-invasive cancer screening;   

DOI  :  10.3389/fonc.2020.610647

来源: DOAJ

【 摘 要 】

Prostate cancer (PCa) diagnosis based on patient urine analysis provides non-invasive and promising method as compared to biopsy and a prostate-specific antigen (PSA) test. This study was conceived to investigate whether Integrin alpha V (ITGAV) protein is present in urine and assess the urinary ITGAV diagnostic potential for PCa. Materials and Methods: Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22). Results: The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p < 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA. Conclusion: Urinary ITGAV provides a novel noninvasive biomarker with high specificity.

【 授权许可】

Unknown